Who is sponsoring NCT04742374?

NCT04742374 is sponsored by Centre Hospitalier Universitaire de Nīmes.

What drugs are being tested in NCT04742374?

Interventions in NCT04742374: Blood sampling.

What condition does NCT04742374 study?

NCT04742374 studies Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.

Is NCT04742374 still recruiting?

NCT04742374 is currently completed. Last updated 10 December 2025.

Last reviewed 2025-12-10 · How we verify

NCT04742374: LYMPHOARESIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Completed EARLY_PHASE1 Last updated 10 December 2025

What this trial tests

EARLY_PHASE1 trial testing Blood sampling in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in 8 participants. Completed in 18 December 2023.

Timeline

12 March 2021

Primary endpoint
18 December 2023

18 December 2023

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nīmes
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	8
Start date	12 March 2021
Primary completion	18 December 2023
Estimated completion	18 December 2023
Sites	1 location across France

Drugs / interventions tested

Blood sampling — full drug profile →

Conditions studied

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating — all drugs for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating →

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

18 and older, any sex, with Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CIDP, a rare disorder affecting young adults, causes gradual weakness of the limbs, areflexia and impaired sensory function. New CIDP phenotypes without antibodies but with modified cell profiles have been described. Treatments include corticotherapy, IVIg and plasmapheresis but the latter's action mechanisms remain unclear. Plasmapheresis supposedly removes toxic agents like antibodies from plasma but it is uncertain whether it has an immune-modulating effect. Also, the refining mechanisms of the two main plasmapheresis techniques - single plasma exchange and double filtration plasmapheresis (DFPP) - are different and unclear. This study aims to compare the evolution of peripheral lymphocyte profiles in patients with CIDP according to their treatment (single centrifugation plasmapheresis or DFPP) to better grasp the action mechanisms of both techniques.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Protocol of comparison of the effects of single plasma exchange and double filtration plasmapheresis on peripheral lymphocyte phenotypes in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: a monocentric prospective study with single-case experimental desig
Moranne O, Ion IM, Cezar R, Messikh Z, et al · · 2022 · cited 2× · PMID 35931957 · DOI 10.1186/s12883-022-02816-w

Verify or expand the search:

Other trials of Blood sampling

Trials testing the same drug.

NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
NCT07237984 — Colorectal Omics and ofCS Proteoglycans (COCO) in Screening and a Diagnostic Pathway · not yet recruiting
NCT06544018 — Circadian Rhythm Deregulation in Patients With CAPS · NA · recruiting
NCT07245550 — Thyroid and Adrenal Disorders in ICU · not yet recruiting
NCT07033091 — Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening · NA · recruiting

Other recruiting trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Currently open trials in the same condition.

NCT05327114 — Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Phase 2, PHASE3 · recruiting

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

NCT07403474 — Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Ther · Phase 4 · not yet recruiting
NCT07455981 — Work Organization and Gambling Addiction · not yet recruiting
NCT07403500 — Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. · NA · not yet recruiting
NCT07342010 — Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT · Phase 4 · not yet recruiting
NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04742374 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nīmes
Last refreshed: 10 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04742374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing